Age and sex modulate metabolic and cardiovascular risk markers of patients after 1 year of highly active antiretroviral therapy (HAART)

Atherosclerosis

Volumn 187, Issue 1, 2006, Pages 177-185

  Leitner, Judith Maria ^a   Pernerstorfer Schoen, Heidemarie ^b,c   Weiss, Alina ^d   Schindler, Karin ^b   Rieger, Armin ^b   Jilma, Bernd ^a  

^a Department of Clinical Pharmacology   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c HANUSCH HOSPITAL   (Austria)

^d GENERAL HOSPITAL LINZ   (Austria)

Author keywords

Adipocytokines; Age; Atherosclerosis; HIV; Hyperlipidemia; Selectins; Sex

Indexed keywords

ABACAVIR; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INDINAVIR; INSULIN; LAMIVUDINE; LEPTIN; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PADGEM PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG RESPONSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL;

ADIPONECTIN; ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; E-SELECTIN; FEMALE; HIV SEROPOSITIVITY; HUMANS; INSULIN; LEPTIN; MALE; MIDDLE AGED; P-SELECTIN; RISK; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 33744547391     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.09.001     Document Type: Article

References (42)

1. Baril L. Fat distribution anomalies and other metabolic disorders in patients under antiretroviral therapy. Presse Med 27 Suppl. 5 (1998) 10-11
2. Calza L., Manfredi R., and Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53 (2004) 10-14
3. Friis-Moller N., Weber R., Reiss P., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. Aids 17 (2003) 1179-1193
4. Bonnet F., Morlat P., Chene G., et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 3 (2002) 195-199
5. Dong Z., and Wagner D. Leukocyte-endothelium adhesion molecules in atherosclerosis. J Lab Clin Med 132 (1998) 369-375
6. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
7. Ridker P., Hennekens C., Roitman-Johnson B., Stampfer M., and Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351 (1998) 88-92
8. Hwang S.J., Ballantyne C.M., Sharrett A.R., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study. Circulation 96 (1997) 4219-4225
9. Tsakiris D.A., Tschopl M., Jager K., et al. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis 142 (1999) 193-200
10. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
11. Soderberg S., Ahren B., Jansson J.H., et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 246 (1999) 409-418
12. Nagy G.S., Tsiodras S., Martin L.D., et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 36 (2003) 795-802
13. Ouchi N., Kihara S., Funahashi T., Matsuzawa Y., and Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14 (2003) 561-566
14. Hanley A.J., Connelly P.W., Harris S.B., and Zinman B. Adiponectin in a native Canadian population experiencing rapid epidemiological transition. Diabetes Care 26 (2003) 3219-3225
15. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
16. Tong Q., Sankale J.L., Hadigan C.M., et al. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 88 (2003) 1559-1564
17. Roldan V., Marin F., Lip G.Y., and Blann A.D. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 90 (2003) 1007-1020
18. Hernandez C., Lecube A., Barbera G., et al. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Med Sci Monit 9 (2003) CR114-CR119
19. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 41 (1992) 1-19
20. Constans J., Pellegrin J.L., Peuchant E., et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 24 (1994) 416-420
21. Blann A.D., Miller J.P., and McCollum C.N. von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis 132 (1997) 151-156
22. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
23. Jilma B., Marsik C., Mayr F., et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 72 (2002) 403-410
24. Landay A.L., and Muirhead K.A. Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol 52 (1989) 48-60
25. Pujari S.N., Dravid A., Naik E., et al. Lipodystrophy and dyslipidemia among patients taking first-line, world health organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 39 (2005) 199-202
26. Gallant J.E., Staszewski S., Pozniak A.L., et al. Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients: a 3 year randomized trial. JAMA 292 (2004) 191-201
27. Havel P.J., Kasim-Karakas S., Dubuc G.R., Mueller W., and Phinney S.D. Gender differences in plasma leptin concentrations. Nat Med 2 (1996) 949-950
28. Rosenbaum M., Nicolson M., Hirsch J., et al. Effects of weight change on plasma leptin concentrations and energy expenditure. J Clin Endocrinol Metab 82 (1997) 3647-3654
29. Jilma B., Eichler H.G., Breiteneder H., et al. Effects of 17 beta-estradiol on circulating adhesion molecules. J Clin Endocrinol Metab 79 (1994) 1619-1624
30. Blann A.D., Amiral J., and McCollum C.N. Circulating endothelial cell/leucocyte adhesion molecules in ischaemic heart disease. Br J Haematol 95 (1996) 263-265
31. Bozzette S.A., Ake C.F., Tam H.K., Chang S.W., and Louis T.A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348 (2003) 702-710
32. Holmberg S.D., Moorman A.C., Williamson J.M., et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360 (2002) 1747-1748
33. Fontas E., Van Leth F., Sabin C.A., et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J Infect Dis 189 (2004) 1056-1074
34. Ferrieres J., Elias A., Ruidavets J.B., et al. Carotid intima-media thickness and coronary heart disease risk factors in a low-risk population. J Hypertens 17 (1999) 743-748
35. Chambless L.E., Heiss G., Folsom A.R., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol 146 (1997) 483-494
36. Seminari E., Pan A., Voltini G., et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 162 (2002) 433-438
37. Stein J.H., Wu Y., Kawabata H., and Iloeje U.H. Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors. Am J Cardiol 92 (2003) 270-274
38. Vigouroux C., Maachi M., Nguyen T.H., et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. Aids 17 (2003) 1503-1511
39. Pernerstorfer-Schoen H., Jilma B., Perschler A., et al. Sex differences in HAART-associated dyslipidaemia. Aids 15 (2001) 725-734
40. Geluk C.A., Halkes C.J., De Jaegere P.P., Plokker T.W., and Cabezas M.C. Daytime triglyceridemia in normocholesterolemic patients with premature atherosclerosis and in their first-degree relatives. Metabolism 53 (2004) 49-53
41. Stavenow L., and Kjellstrom T. Influence of serum triglyceride levels on the risk for myocardial infarction in 12,510 middle aged males: interaction with serum cholesterol. Atherosclerosis 147 (1999) 243-247
42. Abe Y., El-Masri B., Kimball K.T., et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 18 (1998) 723-731